1. Home
  2. ACIW vs NAMS Comparison

ACIW vs NAMS Comparison

Compare ACIW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACIW

ACI Worldwide Inc.

HOLD

Current Price

$54.42

Market Cap

4.5B

Sector

Technology

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$30.89

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACIW
NAMS
Founded
1975
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.7B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
ACIW
NAMS
Price
$54.42
$30.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$62.50
$46.75
AVG Volume (30 Days)
982.7K
977.5K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
13.09
N/A
EPS
0.37
N/A
Revenue
$1,009,780,000.00
N/A
Revenue This Year
$9.67
$17.96
Revenue Next Year
$7.41
$540.65
P/E Ratio
$147.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.05
$21.14
52 Week High
$60.17
$42.21

Technical Indicators

Market Signals
Indicator
ACIW
NAMS
Relative Strength Index (RSI) N/A 40.97
Support Level N/A $29.23
Resistance Level N/A $37.29
Average True Range (ATR) 0.00 1.96
MACD 0.00 -0.43
Stochastic Oscillator 0.00 7.49

Price Performance

Historical Comparison
ACIW
NAMS

About ACIW ACI Worldwide Inc.

ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: